(Q45218162)

English

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

scientific article published in January 2005

Statements

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin (English)
1 January 2005
73-82

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit